Death Spirals Loom for Health Insurers

March 8, 2016

Obamacare enrollment is already millions of people below original forecasts, and we could see two sorts of death spirals in the insurance exchanges of the Affordable Care Act because of premium inflexibility mandated by law and partisan unwillingness to make the necessary compromises to fix it. Read More

When Governments Mandate Transparency of R&D Costs, the Details are Important

March 8, 2016

There has been a new interest in expanding the transparency of pharmaceutical markets, in many areas, including information about the outlays on R&D for the development of specific drugs. The debate over transparency legislation, still pending but stalled in California (AB 463), raised public attention to this issue worldwide and has stimulated additional interest in transparency measures in various states (notably in Colorado) and among members of Congress and in foreign countries. Read More